Message from LeadershipThe 2015 Nobel Prize awarded to Dr. Satoshi Omura for his early research in Japan on the river blindness drug Ivermectin refocused attention on global health R&D. Ivermectin transformed hundreds of millions of lives and communities, and the story of its development represents the power of private-public collaboration, as well as Japan’s legacy of scientific excellence and creativity.
Despite the success of Ivermectin and numerous other global health innovations, extraordinary disease burdens persist in low- and middle-income countries. But we are optimists. We believe that the next game-changing global health tools are within reach. To deliver on the promise of innovation, our work de-risks the global health product development process by facilitating meaningful R&D partnerships between Japan and the world, by helping each sector contribute strengths and capabilities to accelerate global health innovation.
Our role is not simply to reduce the financial burden of global health R&D. Success also depends on how we manage our portfolio of investments, which for us means leveraging the principles of product development used in the private sector for public purposes. In this we are unyielding: we do not accept mediocre results. Too many lives are at stake to pursue candidates that do not show promise. The goal is to keep the valuable time and resources of people and institutions focused on the candidates that do show promise.
The creativity, insight, and commitment of our funders, sponsors, and product development partners inspire our approach and propel our impact. We offer our gratitude and look forward to continued work together toward a healthier, more prosperous world.
Kiyoshi Kurokawa, MD
BT Slingsby, MD, PhD, MPH
Chief Executive Officer